Xinyuan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xinyuan Li has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chunlai Zeng
Department of Cardiology, Central Laboratory of Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People’s Hospital, Lishui, China
1 shared publication - Lihong Jin
Department of Public Health, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang Province, China
1 shared publication - Meixia Ji
Department of Endocrinology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang Province, China
1 shared publication - Xiangying Zhu
Department of Endocrinology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang Province, China
1 shared publication - Xiaoxiao Ji
Center of Health Management, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang Province, China
1 shared publication - Yuanliang Gu
Department of Public Health, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang Province, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e5164386
Development and Validation of an Integrated Metabolism‐Obesity Index for Screening Renal Impairment in Patients With Newly Diagnosed Type 2 Diabetes Mellitus
Background: Diabetic kidney disease, a severe diabetes microvascular complication affecting 30%~40% of diabetic patients, raises end‐stage renal disease and mortality risks. This study is aimed at developing and validate a novel index combining obesity measures and metabolic parameters to screen renal impairment in newly diagnosed T2DM patients. Methods: A total of 387 and 259 newly diagnosed T2DM patients were recruited for model development and validation, respectively. Renal impairment was defined as eGFR < 60 mL/min/1.73 m 2 and/or urinary albumin‐to‐creatinine ratio (UACR) ≥ 30 mg/g. Obesity‐ or metabolism‐related indicators were collected. Significantly independent indicators were selected via bidirectional stepwise regression in the modeling patients to develop a comprehensive index termed InMOI. In the validation patients, restricted cubic spline analysis examined the dose‐response relationship between InMOI and renal impairment, whereas ROC curves assessed the screening performance. Results: The triglyceride‐glucose index (TyG) combined with various obesity measures showed significant associations with renal impairment. The InMOI, derived from TyG‐BMI and TyG‐waist to hip ratio (TyG‐WHR), demonstrated a linear dose‐response relationship with the odds ratio for renal impairment. InMOI achieved an AUC of 0.78 for identifying renal impairment. Optimizing the index by replacing WHR with the visceral‐to‐subcutaneous fat area ratio measured by DEXA, the modified InMOI (m‐InMOI) showed a better performance (AUC = 0.81). Conclusion: This study underscores the value of metabolism‐obesity indices in early detection of diabetic renal damage and highlights the pathogenic role of visceral obesity and metabolic dysregulation in diabetic kidney disease. The InMOI provides a practical tool for large‐scale screening and early prevention of diabetic kidney disease.
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e5164386
Open AccessDevelopment and Validation of an Integrated Metabolism‐Obesity Index for Screening Renal Impairment in Patients With Newly Diagnosed Type 2 Diabetes Mellitus
Background: Diabetic kidney disease, a severe diabetes microvascular complication affecting 30%~40% of diabetic patients, raises end‐stage renal disease and mortality risks. This study is aimed at developing and validate a novel index combining obesity measures and metabolic parameters to screen renal impairment in newly diagnosed T2DM patients. Methods: A total of 387 and 259 newly diagnosed T2DM patients were recruited for model development and validation, respectively. Renal impairment was defined as eGFR < 60 mL/min/1.73 m 2 and/or urinary albumin‐to‐creatinine ratio (UACR) ≥ 30 mg/g. Obesity‐ or metabolism‐related indicators were collected. Significantly independent indicators were selected via bidirectional stepwise regression in the modeling patients to develop a comprehensive index termed InMOI. In the validation patients, restricted cubic spline analysis examined the dose‐response relationship between InMOI and renal impairment, whereas ROC curves assessed the screening performance. Results: The triglyceride‐glucose index (TyG) combined with various obesity measures showed significant associations with renal impairment. The InMOI, derived from TyG‐BMI and TyG‐waist to hip ratio (TyG‐WHR), demonstrated a linear dose‐response relationship with the odds ratio for renal impairment. InMOI achieved an AUC of 0.78 for identifying renal impairment. Optimizing the index by replacing WHR with the visceral‐to‐subcutaneous fat area ratio measured by DEXA, the modified InMOI (m‐InMOI) showed a better performance (AUC = 0.81). Conclusion: This study underscores the value of metabolism‐obesity indices in early detection of diabetic renal damage and highlights the pathogenic role of visceral obesity and metabolic dysregulation in diabetic kidney disease. The InMOI provides a practical tool for large‐scale screening and early prevention of diabetic kidney disease.